ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells $23,816.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 400 shares of the company’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $59.54, for a total transaction of $23,816.00. Following the transaction, the vice president now owns 83,478 shares of the company’s stock, valued at $4,970,280.12. This represents a 0.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Meredith Cook also recently made the following trade(s):

• On Monday, January 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $53.92, for a total transaction of $21,568.00.

ANI Pharmaceuticals Trading Down 0.2 %

Shares of ANIP opened at $58.82 on Wednesday. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $70.81. The firm has a 50-day moving average price of $56.98 and a 200 day moving average price of $58.23. The firm has a market capitalization of $1.24 billion, a P/E ratio of -106.94 and a beta of 0.74.

Analysts Set New Price Targets

A number of brokerages have recently commented on ANIP. Truist Financial increased their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research report on Tuesday, October 22nd. Leerink Partners began coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 target price for the company. Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. StockNews.com upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, February 5th. Finally, HC Wainwright reiterated a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $77.71.

Institutional Investors Weigh In On ANI Pharmaceuticals

Hedge funds have recently modified their holdings of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in ANI Pharmaceuticals by 41.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 47,899 shares of the specialty pharmaceutical company’s stock worth $2,648,000 after buying an additional 13,948 shares during the period. Stonepine Capital Management LLC purchased a new position in ANI Pharmaceuticals during the fourth quarter worth about $1,128,000. Rafferty Asset Management LLC purchased a new position in ANI Pharmaceuticals during the fourth quarter worth about $200,000. ProShare Advisors LLC boosted its stake in ANI Pharmaceuticals by 29.0% during the fourth quarter. ProShare Advisors LLC now owns 6,532 shares of the specialty pharmaceutical company’s stock worth $361,000 after buying an additional 1,469 shares during the period. Finally, Nomura Holdings Inc. boosted its stake in ANI Pharmaceuticals by 1.5% during the fourth quarter. Nomura Holdings Inc. now owns 213,879 shares of the specialty pharmaceutical company’s stock worth $11,823,000 after buying an additional 3,255 shares during the period. Hedge funds and other institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.